Neoadjuvant anti-HER2 targeted therapy in combination with chemotherapy is the standard of care for patients with HER2+ early stage breast cancer regardless of estrogen receptor (ER) status2,3. This evidence concerns the gene ERBB2 and breast carcinoma.